![Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease](https://pharmashots.com/public/images/20211116012113_original_27.webp)
Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease
![Teva's generic of Quartette® Tablets: Rivelsa® (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets Teva's generic of Quartette® Tablets: Rivelsa® (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets](https://www.tevagenerics.com/globalassets/products/image//R-Z/Rive6031.jpg)
Teva's generic of Quartette® Tablets: Rivelsa® (levonorgestrel/ethinyl estradiol and ethinyl estradiol) Tablets
![Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease](https://pharmashots.com/public/images/20211116015345_original_18.webp)
Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease
![Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease](https://pharmashots.com/public/images/20211116011931_original_40.webp)
Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease
![Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer | BioSpace Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer | BioSpace](https://mms.businesswire.com/media/20200806005082/en/755088/3/1200px-Daiichi_Sankyo_logo.svg.jpg)
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer | BioSpace
![Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease](https://pharmashots.com/wp-content/uploads/2021/06/Teva-2-455x300.jpg)
Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease
![Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease Teva Signs an Exclusive WW License Agreement with Modag to Develop Anle138b and Sery433 for Neurodegenerative Disease](https://pharmashots.com/public/images/20211116004227_original_41.webp)